 |
|
|
 |
Development and Validation of a Preference Weight Multiattribute Health Outcome Measure for Rheumatoid Arthritis
CHIUN-FANG CHIOU, MARIA E. SUAREZ-ALMAZOR, CATHY D. SHERBOURNE, CHIH-HUNG CHANG, CAROLINA REYES, MICHELLE DYLAN, JOSHUA OFMAN, DANIEL J. WALLACE, WESLEY MIZUTANI, and MICHAEL WEISMAN ABSTRACT. Objective. To develop and validate multiattribute measures for patients with rheumatoid arthritis (RA) to report health states and estimate preference weights. Methods. Survey materials were mailed to 748 patients. Factor analysis, an item response theory-based model, and an internal consistency test were used to identify attributes and evaluate items. Two multiattribute preference weight functions (MAPWF) were constructed. Construct validity of the new measures was then tested. Results. Four hundred eighty-seven patients returned the survey; 24 items on 6 health attributes were selected to form the new outcomes measure. Two MAPWF were derived with preference weights measured with time tradeoff and visual analog scales as dependent variables. All validity test results were statistically significant. Conclusion. Our results reveal that the new measures are reliable and valid in assessing health states and associated preference weights of patients with RA. (First Release Oct 15 2006; J Rheumatol 2006;33:2409–11) Key Indexing Terms:
RHEUMATOID ARTHRITIS From Amgen, Inc., Thousand Oaks, California; Health Services Research, Baylor College of Medicine, Houston, Texas; Health Program, RAND Corporation, Santa Monica, California; Feinberg School of Medicine, Northwestern University, Chicago, Illinois; Genentech, South San Francisco; Cerner LifeSciences, a Cerner Company, Beverly Hills; Departments of Medicine and Rheumatology, Cedars-Sinai Health System, Los Angeles; and Talbert Medical Group, Huntington Beach, California, USA. Supported by a grant from Amgen, Inc. C-F. Chiou, PhD, Amgen, Inc; M.E. Suarez-Almazor, MD, PhD, Health Services Research, Baylor College of Medicine; C.D. Sherbourne, PhD, Health Program, RAND Corporation; C-H. Chang, PhD, Feinberg School of Medicine, Northwestern University; C. Reyes, PhD, Genentech; M. Dylan, PhD, Senior Research Associate, Cerner LifeSciences; J. Ofman, MD, MSHS, Amgen, Inc; D.J. Wallace, MD, Departments of Medicine and Rheumatology, Cedars-Sinai Health System; W. Mizutani, MD, Talbert Medical Group; M. Weisman, MD, Departments of Medicine and Rheumatology, Cedars-Sinai Health System. Address reprint requests to Dr. M. Dylan, Cerner LifeSciences, 9100 Wilshire Blvd., Suite 655E, Beverly Hills, CA 90212, USA. E-mail: mdylan@cerner.com Accepted for publication August 2, 2006.
|
